Compare Arko Corp. (ARKO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs Viatris Inc — how do they compare? Arko Corp. trades at $4.5 (market cap $493.06M), while Viatris Inc trades at $16.22 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 37.9× Arko Corp.'s market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| ARKO | VTRS | |
|---|---|---|
Market Cap | $493.06M | $18.69B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.64 | $17.86 |
52-Week Low | $3.82 | $9.49 |
Enterprise Value | $2.67B | $30.80B |
Dividend Yield | 2.73% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO trades at $4.51, down 4.04% amid a bearish technical trend. The stock shows mixed fundamentals: revenue declined to $7.64B in 2025, but net income improved to $22.74M. Recent Q2 2026 earnings missed estimates, with EPS of $0.04 versus $0.15 expected. The company maintains a dividend, paying $0.03 per share semi-annually, and holds a low P/S ratio of 0.06, though the P/E is elevated at 54.94. Analyst sentiment is neutral with all three covering analysts rating it Hold.
Outlook remains cautious due to declining revenue trends and competitive pressures in the convenience store sector. The stock's low price near recent support levels may attract value investors, but risks include volatile fuel margins and high debt. Institutional interest is present, with Dimensional Fund Advisors increasing its stake by 7.3% in Q2 2026.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
